ArticleCurrent issues in molecular biology2026
Sex-Dependent Effects of Exogenous Irisin on Pancreatic Endocrine-Cell Immunophenotype in Post-Weaning Wistar Rats.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesIrisin is an exercise-associated myokine with reported effects on β-cell survival, insulin secretion, and pancreatic tissue protection in experimental models of metabolic stress. However, less is known about its influence on the developing endocrine pancreas under physiological conditions. Accordingly, the aim of the present study was to determine whether exogenous recombinant FNDC5/irisin is associated with changes in pancreatic endocrine-cell immunophenotype and islet-level markers of cell turnover in male and female Wistar rats.
methodsThirty-two 3-week-old Wistar rats were assigned to control and irisin-treated groups, with males and females analyzed searately. Irisin was administered intraperitoneally at 100 µg/kg body weight once weekly for four weeks. Control animals received 0.9% NaCl. At the end of the experiment, serum cholesterol, fructosamine, and lipase were measured as supportive biochemical endpoints. Pancreatic sections were analyzed immunohistochemically for insulin, glucagon, somatostatin, PCNA, and cleaved caspase-3.
resultsIrisin treatment was not associated with statistically significant changes in serum cholesterol, fructosamine, or lipase. In males, irisin increased insulin immunoreactive area, insulin-positive cell percentage, and insulin-positive cell density. In females, irisin decreased glucagon immunoreactive area and glucagon-positive cell density, whereas glucagon-positive cell percentage remained unchanged. Somatostatin immunoreactive area decreased after irisin administration in both sexes, while somatostatin-positive cell percentage and density increased in males and females. PCNA-positive cell percentage decreased in both sexes after irisin treatment. Islet cleaved caspase-3 immunoreactivity, assessed as optical density, was not significantly altered.
conclusionsExogenous irisin modified pancreatic endocrine-cell immunophenotype in a sex- and cell-type-dependent manner in post-weaning rats. These changes occurred without significant alterations in serum lipase, fructosamine, or cholesterol and without a detectable increase in islet cleaved caspase-3 immunoreactivity under the applied analytical conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.